Metraipolis › archive › dc_f53f82de2a67

GeneDx — Wikipedia (en)

Source: Wikipedia (en)
Original: https://en.wikipedia.org/wiki/GeneDx
License (as archived): CC-BY-SA-4.0
Archived: 2026-10-15T17:42:30.543Z
SHA-256 of the archived text: 7cf8a299c74a127fa7ef1d12d711c062c583ffee194ae73fe5fd5d94020fa554
Stable URL of this page: https://metraipolis.com/documento/dc_f53f82de2a67

How to cite

GeneDx — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/GeneDx (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_f53f82de2a67 (Metraipolis archive dc_f53f82de2a67, sha256 7cf8a299c74a127fa7ef1d12d711c062c583ffee194ae73fe5fd5d94020fa554)

BibTeX

@misc{dcf53f82de2a67,
  title = {GeneDx — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/GeneDx},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_f53f82de2a67; sha256 7cf8a299c74a127fa7ef1d12d711c062c583ffee194ae73fe5fd5d94020fa554},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/GeneDx. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

GeneDx is an American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing (WGS) and whole exome sequencing (WES) for the diagnosis of rare and inherited disorders. The company provides genetic testing services to healthcare providers, hospitals, and health systems, and contributes to advancements in genomic medicine through research, biopharma partnerships, and advocacy. The company is headquartered in Stamford, Connecticut, with its clinical laboratory in Gaithersburg, Maryland, and is publicly traded on the Nasdaq under the ticker symbol WGS. GeneDx was founded in 2000 by Sherri Bale and John Compton, scientists from the National Institutes of Health (NIH), to provide diagnostic services for patients with rare and ultra-rare disorders. The company was acquired by BioReference Laboratories in 2006 and subsequently by Sema4 in 2022, after which it underwent a strategic transformation refocusing on whole exome and genome sequencing in pediatrics and changed its name to GeneDx. Since launching exome testing in 2011, the company has built GeneDx Infinity, a rare disease dataset including more than one million clinically sequenced exomes and genomes, more than 2.5 million tests, and more than 8 million phenotypic datapoints. In 2024, GeneDx reported revenue of $302.3 million, representing 56% year-over-year growth, and announced its first profitable quarter. For full-year 2025, the company reported revenue of approximately $427 million.

Tema degli esploratori: scienze della vita e salute (deposito sistematico; categoria «Genetics»).
Fonte: Wikipedia in inglese, voce «GeneDx» — https://en.wikipedia.org/wiki/GeneDx
Wikidata Q5531048: «American biotechnology company» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q5531048
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/GeneDx?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1378738889, consultata il 2026-10-15T16:50:02.718Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 46449fc854afe02fe9aa84ef2989e5a62372220f43461a92e36d4a8633c51090